Selecta Biosciences, Inc. Working Capital

Working Capital of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending December 30, 2020 was $69.8 Million (a -22.01% decrease compared to previous quarter)
  • Year-over-year quarterly Working Capital increased by 57.31%
  • Annual Working Capital for 2020 was $69.8 Million (a 13.08% increase from previous year)
  • Annual Working Capital for 2019 was $61.7 Million (a 790.42% increase from previous year)
  • Annual Working Capital for 2018 was $6.93 Million (a -92.1% decrease from previous year)
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Selecta Biosciences, Inc.

Most recent Working Capitalof SELB including historical data for past 10 years.

Interactive Chart of Working Capital of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $69.8 $89.5 $38.54 $44.37 $69.8
2019 $61.72 $6.64 $12.54 $26.48 $61.72
2018 $6.93 $20.94 $54.94 $73.17 $6.93
2017 $87.71 $96.03 $94.53 $58.18 $87.71
2016 $73.11 $75.71 $80.11 $73.11
2015 $31.62
2014 $9.88 $9.88

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.